We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?
Read MoreHide Full Article
Key Takeaways
GEHC's Imaging and PDx segments led Q1 with strong organic growth and expanding EBIT margins.
Tariff-related costs are expected to hit Q2 earnings by nearly $100 million despite mitigation efforts.
GEHC launched Flyrcado and plans a regulatory submission for photon-counting CT later this year.
GE HealthCare Technologies Inc. (GEHC - Free Report) is scheduled to report second-quarter 2025 results on July 30, before market open.
In the last reported quarter, the company delivered an earnings surprise of 10.99%. GEHC’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.92%.
Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $4.97 billion, implying growth of 2.8% year over year.
The Zacks Consensus Estimate for earnings per share is pinned at $0.91, suggesting a decline of 9% from the prior-year level.
GEHC’s Segmental Overview
GE HealthCare’s Imaging segment remains the company’s cornerstone for revenue and margin growth heading into the second quarter. In the first quarter, Imaging delivered 5% organic revenue growth, with strength concentrated in the United States. The segment also posted a 130-basis point year-over-year expansion in EBIT margin, supported by improved productivity, higher volumes, and favorable pricing. Continued investment in R&D and sustained demand across large enterprise accounts in the United States and EMEA regions are expected to carry that momentum into the second quarter, despite ongoing weakness in China.
Advanced Visualization Solutions(AVS) continued to perform steadily, achieving 3% organic revenue growth year over year in the first quarter. The U.S. market drove most of this growth, particularly in advanced ultrasound and interventional guidance technology. EBIT margin for the segment expanded slightly by 10 basis points, aided by volume leverage and productivity improvements. With a growing focus on digital tools and AI integration and the company’s increasing push toward recurring revenue, this segment is expected to maintain a stable trajectory in the second quarter.
Patient Care Solutions(PCS) showed signs of improvement on the revenue side, with organic growth of 2% in the first quarter of 2025 compared to the same period last year. Growth was driven by better backlog execution, particularly in U.S. monitoring solutions. However, the segment’s EBIT margin declined by 450 basis points year over year, largely due to the impact of tariffs, continued investment, and an unfavorable product mix. As GE HealthCare works to launch new higher-margin products and streamline its factory and supplier base, modest revenue growth is anticipated in the second quarter. However, margin recovery may take longer to materialize.
Pharmaceutical Diagnostics(PDx) delivered one of the strongest performances across the portfolio in the first quarter. The segment recorded 8% organic revenue growth and maintained an EBIT margin above 32%. Growth was supported by increased procedure volumes and positive pricing dynamics. GE HealthCare also launched its new radiopharmaceutical Flyrcado during the quarter and saw ongoing strength from Vizamyl. Additionally, the completion of its acquisition of the remaining stake in Nihon Medi-Physics is expected to contribute around $150 million of inorganic revenue through the rest of the year. As demand for PET imaging grows and reimbursement trends remain favorable, the segment is well-positioned for another strong performance in the soon-to-be-reported quarter.
GE HealthCare Technologies Inc. Price and EPS Surprise
One of the most important overhangs for GE HealthCare heading into the second quarter is the impact of tariffs. The company expects approximately 85 cents in adjusted EPS drag from tariffs for the full year, with the majority of that hitting in the second, third, and fourth quarters. For the second quarter alone, GEHC anticipates a tariff-related impact of just under $100 million. Management has already implemented several mitigation strategies, such as duty drawback programs and supply chain optimization, but the lag from high-cost inventory running through the P&L will remain a headwind. Investors will likely look for updates on how further mitigation efforts are progressing and how those are shaping expectations for the remainder of the year.
Innovation remains a central theme for GEHC’s long-term growth narrative. The company officially launched Flyrcado, its PET imaging tracer for coronary artery disease, and received CMS pass-through reimbursement in April. Early adoption trends and expansion of its radiopharmaceutical manufacturing network will be areas of investor interest. Additionally, GEHC is on track for regulatory submission of its photon-counting CT system later this year, a technology that promises higher resolution imaging and improved diagnostics. With robust clinical and product pipelines in place, any new updates on launch timelines or commercial traction may influence the outlook for second-half growth.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for GEHC this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3 at present.
Stocks Worth a Look
Here are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time:
GeneDx Holdings (WGS - Free Report) has an Earnings ESP of +5.26% and a Zacks Rank #2. The company is slated to release second-quarter 2025 results on July 29.
WGS’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 145.82%. The Zacks Consensus Estimate for the company’s second-quarter EPS is expected to increase 190.9% from the year-ago quarter figure.
Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank #2. The company is set to release third-quarter fiscal 2025 results on Aug. 6.
COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%. The Zacks Consensus Estimate for COR’s fiscal third-quarter EPS is expected to surge 13.2% from the year-ago reported figure.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +0.72% and a Zacks Rank #2. The company is slated to release fourth-quarter fiscal 2025 results on Aug. 12.
CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%. The Zacks Consensus Estimate for the company’s fiscal fourth-quarter EPS is expected to increase 10.3% from the year-ago quarter figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) is scheduled to report second-quarter 2025 results on July 30, before market open.
In the last reported quarter, the company delivered an earnings surprise of 10.99%. GEHC’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.92%.
Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $4.97 billion, implying growth of 2.8% year over year.
The Zacks Consensus Estimate for earnings per share is pinned at $0.91, suggesting a decline of 9% from the prior-year level.
GEHC’s Segmental Overview
GE HealthCare’s Imaging segment remains the company’s cornerstone for revenue and margin growth heading into the second quarter. In the first quarter, Imaging delivered 5% organic revenue growth, with strength concentrated in the United States. The segment also posted a 130-basis point year-over-year expansion in EBIT margin, supported by improved productivity, higher volumes, and favorable pricing. Continued investment in R&D and sustained demand across large enterprise accounts in the United States and EMEA regions are expected to carry that momentum into the second quarter, despite ongoing weakness in China.
Advanced Visualization Solutions(AVS) continued to perform steadily, achieving 3% organic revenue growth year over year in the first quarter. The U.S. market drove most of this growth, particularly in advanced ultrasound and interventional guidance technology. EBIT margin for the segment expanded slightly by 10 basis points, aided by volume leverage and productivity improvements. With a growing focus on digital tools and AI integration and the company’s increasing push toward recurring revenue, this segment is expected to maintain a stable trajectory in the second quarter.
Patient Care Solutions(PCS) showed signs of improvement on the revenue side, with organic growth of 2% in the first quarter of 2025 compared to the same period last year. Growth was driven by better backlog execution, particularly in U.S. monitoring solutions. However, the segment’s EBIT margin declined by 450 basis points year over year, largely due to the impact of tariffs, continued investment, and an unfavorable product mix. As GE HealthCare works to launch new higher-margin products and streamline its factory and supplier base, modest revenue growth is anticipated in the second quarter. However, margin recovery may take longer to materialize.
Pharmaceutical Diagnostics(PDx) delivered one of the strongest performances across the portfolio in the first quarter. The segment recorded 8% organic revenue growth and maintained an EBIT margin above 32%. Growth was supported by increased procedure volumes and positive pricing dynamics. GE HealthCare also launched its new radiopharmaceutical Flyrcado during the quarter and saw ongoing strength from Vizamyl. Additionally, the completion of its acquisition of the remaining stake in Nihon Medi-Physics is expected to contribute around $150 million of inorganic revenue through the rest of the year. As demand for PET imaging grows and reimbursement trends remain favorable, the segment is well-positioned for another strong performance in the soon-to-be-reported quarter.
GE HealthCare Technologies Inc. Price and EPS Surprise
GE HealthCare Technologies Inc. price-eps-surprise | GE HealthCare Technologies Inc. Quote
Other Factors to Note
One of the most important overhangs for GE HealthCare heading into the second quarter is the impact of tariffs. The company expects approximately 85 cents in adjusted EPS drag from tariffs for the full year, with the majority of that hitting in the second, third, and fourth quarters. For the second quarter alone, GEHC anticipates a tariff-related impact of just under $100 million. Management has already implemented several mitigation strategies, such as duty drawback programs and supply chain optimization, but the lag from high-cost inventory running through the P&L will remain a headwind. Investors will likely look for updates on how further mitigation efforts are progressing and how those are shaping expectations for the remainder of the year.
Innovation remains a central theme for GEHC’s long-term growth narrative. The company officially launched Flyrcado, its PET imaging tracer for coronary artery disease, and received CMS pass-through reimbursement in April. Early adoption trends and expansion of its radiopharmaceutical manufacturing network will be areas of investor interest. Additionally, GEHC is on track for regulatory submission of its photon-counting CT system later this year, a technology that promises higher resolution imaging and improved diagnostics. With robust clinical and product pipelines in place, any new updates on launch timelines or commercial traction may influence the outlook for second-half growth.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for GEHC this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3 at present.
Stocks Worth a Look
Here are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time:
GeneDx Holdings (WGS - Free Report) has an Earnings ESP of +5.26% and a Zacks Rank #2. The company is slated to release second-quarter 2025 results on July 29.
WGS’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 145.82%. The Zacks Consensus Estimate for the company’s second-quarter EPS is expected to increase 190.9% from the year-ago quarter figure.
Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank #2. The company is set to release third-quarter fiscal 2025 results on Aug. 6.
COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%. The Zacks Consensus Estimate for COR’s fiscal third-quarter EPS is expected to surge 13.2% from the year-ago reported figure.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +0.72% and a Zacks Rank #2. The company is slated to release fourth-quarter fiscal 2025 results on Aug. 12.
CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%. The Zacks Consensus Estimate for the company’s fiscal fourth-quarter EPS is expected to increase 10.3% from the year-ago quarter figure.